Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.

Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.

Korean companies, including large conglomerates and non-biopharmas, are increasingly jumping into biologics manufacturing through cross-border acquisitions following the successes of Samsung and SK.

Biogen’s biosimilars business took a hit in Q1 following pricing pressures and negative currency fluctuations, with the company now prioritizing the rebuilding of the segment.